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Mitochondria are essential for cellular function due to their role in ATP production, calcium homeostasis and apoptotic
signalling. Neurons are heavily reliant on mitochondrial integrity for their complex signalling, plasticity and excitability
properties, and to ensure cell survival over decades. The maintenance of a pool of healthy mitochondria that can meet the
bioenergetic demands of a neuron, is therefore of critical importance; this is achieved by maintaining a careful balance
between mitochondrial biogenesis, mitochondrial trafficking, mitochondrial dynamics and mitophagy. The molecular
mechanisms that underlie these processes are gradually being elucidated. It is widely recognized that mitochondrial
dysfunction occurs in many neurodegenerative diseases, including Parkinson’s disease. Mitochondrial dysfunction in the form
of reduced bioenergetic capacity, increased oxidative stress and reduced resistance to stress, is observed in several Parkinson’s
disease models. However, identification of the recessive genes implicated in Parkinson’s disease has revealed a common
pathway involving mitochondrial dynamics, transport, turnover and mitophagy. This body of work has led to the hypothesis
that the homeostatic mechanisms that ensure a healthy mitochondrial pool are key to neuronal function and integrity. In this
paradigm, impaired mitochondrial dynamics and clearance result in the accumulation of damaged and dysfunctional
mitochondria, which may directly induce neuronal dysfunction and death. In this review, we consider the mechanisms by
which mitochondrial dysfunction may lead to neurodegeneration. In particular, we focus on the mechanisms that underlie
mitochondrial homeostasis, and discuss their importance in neuronal integrity and neurodegeneration in Parkinson’s disease.
LINKED ARTICLES
This article is part of a themed issue on Mitochondrial Pharmacology: Energy, Injury & Beyond. To view the other articles in
this issue visit http://dx.doi.org/10.1111/bph.2014.171.issue-8
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Introduction
In humans, the brain uses more energy than any other organ,
accounting for approximately 20% of the body’s total
demand (Sokoloff, 1960; Clarke and Sokoloff, 1999). Mito-
chondria are tiny powerhouses that play a critical role in
supplying the brain with energy. They provide energy by
coupling the pumping of protons through the inner mito-
chondrial membrane (IMM) to the generation of ATP by ATP
synthase, a highly complex molecular machine. It is accepted
that acquisition of mitochondria by ancestral eukaryotic cells
represents a crucial event in evolution (Gray et al., 1999); this
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allowed the appearance of highly evolved multicellular life
forms on our planet, eventually including humans with
complex brains. Mitochondria do not only play a key role in
supplying energy to cells, but they are also capable of causing
cell death through the activation of cellular suicide pro-
grammes (reviewed in Youle and Strasser, 2008). Critically,
uncontrolled cell proliferation or cell death can result in
diseases such as cancer or neurodegeneration. Human cells
contain several mitochondria, and each organelle contains
multiple copies of a small genome encoded by the mitochon-
drial DNA (mtDNA; Legros et al., 2004). Human mitochon-
dria are the result of uniparental inheritance from the
maternal line. Mitochondrial mass and function differ signifi-
cantly across different cell types, and are dynamically regu-
lated by a variety of physiological cues, including physical
activity and nutrient availability. An increase in mitochon-
drial numbers in individual cells is mediated by mitochondria
biogenesis, a process involving the synthesis and import of
macromolecules to existing mitochondria and the replication
of the mtDNA. This is followed by the fission of one mito-
chondrion into two daughter mitochondria. Mitochondria
accumulate damage during cell life as a consequence of their
metabolic functions. Cells have, therefore, evolved multiple
redundant quality control (QC) mechanisms to cope with
mitochondrial damage. These mechanisms include the
removal of damaged components from the organelles
through the molecular QC pathways or, in extreme cases, the
total removal of damaged mitochondria through autophagic
degradation of the organelles (mitophagy); this is known as
the organellar QC pathway (reviewed in de Castro et al.,
2011; Rugarli and Langer, 2012).
Mitochondrial bioenergetics, homeostasis and QC are
particularly important in human neurons, which are post-
mitotic cells that perform complex functions over many
decades. Mitochondrial dysfunction has been implicated in
many neurodegenerative diseases.
Parkinson’s disease (PD) is the second most common neu-
rodegenerative disease, affecting 1–2% of people over 65 years
of age. It is characterized by the progressive loss of dopamin-
ergic and non-dopaminergic neurons, and the development
of intracellular aggregates of the protein α-synuclein (α-syn).
The majority of PD is sporadic (90–95% of the cases),
but approximately, 5–10% of cases are inherited through
PD-related genes (Bonifati, 2007; Gasser, 2009). Decades of
investigation of toxin-based models of PD, genetic models of
PD and sporadic PD, have unveiled a number of potential
molecular biomarkers of pathology that include protein
aggregation, proteasomal stress, oxidative stress, mitochon-
drial dysfunction, lysosomal dysfunction and aberrant
autophagy (reviewed in Dexter and Jenner, 2013). A robust
molecular biomarker should be related to the fundamental
features of neuropathology and its mechanism, and should
also correlate with disease progression. Perhaps, unsurpris-
ingly, there is no identified biomarker that can be found
uniformly in all the genetic models and also in sporadic PD.
One of the most ubiquitous markers is the presence of α-syn
aggregation, and this is seen in all sporadic disease, but may
be absent in certain genetic forms of PD such as PARKIN-
associated PD. Oxidative stress is described in many studies of
sporadic PD, toxin models and certain genetic models (in
particular, models based on pink1, parkin, DJ-1 and α-syn),
although it remains controversial whether this is a bystander
effect of neurotoxicity or a primary pathogenic process.
Interpreting this data is complicated by the fact that any
biomarker of sporadic PD can only be identified from post-
mortem tissue or CSF, where dissection of primary and sec-
ondary mechanisms is not possible. Lysosomal dysfunction
and aberrant chaperone-mediated autophagy is prominent
in certain genetic models of PD (based on mutations in
ATP13A2, GBA and α-syn), and altered expression of markers
such as LAMP2A and hsp70 in the substantia nigra (SN) of
sporadic PD (Alvarez-Erviti et al., 2010). Models based on
adenoviral delivery of wild-type (Lundblad et al., 2012) or
A53T mutant α-syn (Chung et al., 2009) to rat nigral neurons
have demonstrated altered vesicle exocytosis and impaired
dopaminergic neurotransmission. These events are followed
by axonal damage, with dystrophic swollen axons and aber-
rant axonal transport. Interestingly, the axonopathy occurs as
an early feature and precedes neuronal death, and has thus
been proposed to be a possible early biomarker in these
models. In addition, an α-syn-induced increase in activated
microglia was reported in this model, with a concomitant
increase in striatal cytokines, suggesting that the inflamma-
tory response may also be an early biomarker for disease. It is
evident that the cellular processes of protein degradation,
protein aggregation, oxidative stress and mitochondrial func-
tion interact with each other, and so their coexistence as
possible biomarkers of disease is frequently seen in models.
The role of this review is to address the importance and
relevance of mitochondrial dysfunction as a biomarker for
the pathogenesis of PD. Interestingly, the autosomal reces-
sive forms of the disease are caused by loss of function muta-
tions in genes encoding proteins that intrinsically localize to
mitochondria (phosphatase and tensin homologue-induced
putative kinase 1, DJ-1), or that relocate to this organelle
upon mitochondrial damage (PARKIN), where they appear to
regulate mitochondrial function. Mitochondrial dysfunction
has also been reported in models based on the autosomal
dominant forms of PD (α-syn, LRRK2), and these proteins
have been shown to localize to mitochondria (Devi et al.,
2008) (Papkovskaia et al., 2012). Mitochondrial toxins have
been used for many years to generate animal models of PD
that recapitulate varying degrees of the sporadic disease.
Taken together, these data strongly suggest a potential role
for mitochondrial dysfunction in the pathogenesis of PD.
However, several important questions remain. It is not
known if the observed mitochondrial pathology is the
primary cause of pathogenesis in PD, or if mitochondrial
damage is a consequence of damaged neurons. In addition,
the specific mitochondrial processes involved in neurotoxic-
ity in PD models and in the disease itself remain to be elu-
cidated. Finally, it is unclear what the physiological roles of
the PD proteins are in mitochondrial health. Here, we
provide an overview of some of the recent advances in our
understanding of the role of mitochondrial dysfunction in
PD. We address the evidence for all aspects of mitochondrial
pathology observed in different disease models, and we place
particular emphasis on the emerging data regarding the
mitochondrial QC pathways. We reflect on the relative
importance of these pathways in PD, and how recent
advances in our understanding of such pathways may direct
better therapeutic approaches in the future.
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Mitochondrial bioenergetics and PD
The major mitochondrial function is generation of ATP, the
main energy source for cells. Neurons are heavily reliant on
mitochondrial ATP production for a range of high energy-
demanding processes, including the maintenance of ion gra-
dients through ATP-dependent pumps, axonal transport and
synaptic neurotransmission. The respiratory chain is situated
in the IMM and consists of four multiprotein redox com-
plexes and two mobile electron carriers. The transfer of
electrons from NADH and flavin adenine dinucleotide to
oxygen, occurs through a series of redox reactions. The
energy released by oxidation generates a proton gradient
across the IMM that is used by complex V for the synthesis of
ATP (oxidative phosphorylation). As the electrons flow
through the respiratory chain, there is a small constitutive
leak of high-energy electrons that are able to react with
oxygen, and generate a free radical superoxide anion. Com-
plexes I and III are the major sites of superoxide production.
The brain consumes a disproportionate amount of oxygen
compared with the rest of the body, and an estimated 2%
of this oxygen will be converted to superoxide. Partially
reduced forms of oxygen are highly active; they chemically
interact with biological molecules, resulting in oxidation of
protein, DNA and RNA, and peroxidation of lipids. Thus,
cells also possess a range of mechanisms to neutralize the free
radicals, including small-molecule antioxidants, such as glu-
tathione and vitamin E, and antioxidant enzymes such as
superoxide dismutase, glutathione peroxidase and catalase.
When the balance of reactive oxygen species (ROS) produc-
tion and antioxidant defence is perturbed, accumulation of
excessive ROS occurs in a state termed ‘oxidative stress’
(reviewed in Moran et al., 2012). Of note, there is an age-
related increase in mitochondrial ROS production, with a
concomitant reduction in antioxidant defences, particularly
in post-mitotic cells such as neurons. In the mitochondrial
theory of aging, an age-related decline in the function of the
respiratory chain causes increasing ROS, with subsequent
accumulation of mtDNA mutations (reviewed in Wallace,
2005). These alterations result in progressively deficient res-
piratory chain components, which lead to impaired respira-
tion and further oxidative stress. This may render aged
neurons more susceptible to cell death in late onset neuro-
degenerative diseases.
Studies of post-mortem brains have demonstrated that
there is significant evidence for oxidative stress in PD;
there are increased levels of lipid peroxidation (in the
form of malondialdehyde and 4-hydroxynonenal), increased
levels of protein carbonyls and increased levels of 8-
hydroxydeoxyguanosine in the PD brain, compared with
controls (Dalfo et al., 2005; Seet et al., 2010). The major
source of the oxidative stress is postulated to be an increase in
ROS production induced by inhibition of respiration. Inhibi-
tion of respiration leads to a block in the electron transfer
along the respiratory chain, increases the leak of high-energy
electrons that form free radicals and concomitantly reduces
ATP production. Indeed, complex I deficiency and reduction
in glutathione are observed in the SN of PD patients
(reviewed in Smeyne and Smeyne, 2013), and has been vari-
ably reported in other tissues, including platelets, lympho-
cytes and skeletal muscle (reviewed in (Schapira, 2008).
Models of PD that are based on the administration of
toxins have demonstrated repeatedly that complex I inhibi-
tion is sufficient to cause dopaminergic neuronal toxicity
by inducing a mitochondrial bioenergetic deficit (reviewed
in Martinez and Greenamyre, 2012). Intoxication with 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induces
an acute and irreversible version of parkinsonism in
humans (Langston and Ballard, 1983). MPTP-treated pri-
mates develop nigrostriatal degeneration and clinical
symptoms of PD (Burns et al., 1983). MPTP-treated mice
develop nigral dopaminergic (DA) neuron loss, neuronal
inclusions of α-syn and progressive behavioural deficits
(Fornai et al., 2005). The active toxic species, MPP+, binds
complex I and disrupts electron flow along the respiratory
chain, resulting in lowered ATP production and increased
ROS production. Mice overexpressing Cu/Zn SOD (SOD2),
have reduced MPTP-induced neuronal death (Przedborski
et al., 1992).
Rotenone is a specific mitochondrial complex I inhibitor
that results in increased leakage of electrons and, thus,
increased superoxide generation. Chronic infusion of rote-
none in rats (Betarbet et al., 2000) or chronic oral adminis-
tration in mice (Inden et al., 2011), results in selective loss of
nigral DA neurons and the presence of neuronal α-syn-
positive inclusions, as well as behavioural and motor symp-
toms akin to PD. Although rotenone is lipophilic, it crosses
the blood brain barrier, and results in a systemic complex I
deficit, that is selectively toxic to DA neurons.
Models based on the genes known to cause autosomal
recessive and dominant forms of PD also point to the impor-
tance of mitochondrial bioenergetics in disease pathogen-
esis. PINK1 is a mitochondrial kinase, and there is strong
evidence for its role in mitochondrial bioenergetics. pink1-
deficient Drosophila melanogaster (Clark et al., 2006) and
pink1 knockout mouse models (Gautier et al., 2008) all share
common features of mitochondrial abnormalities (Gispert
et al., 2009; Heeman et al., 2011), increased ROS production
and increased sensitivity to oxidative stress, albeit in the
absence of neurodegeneration. Of note, vitamin K2, which
acts as an electron transporter in Drosophila, is able to
improve electron transfer in pink1-deficient Drosophila
models and in complex I inhibition models, and thus
restores ATP production and rescues the mitochondrial
pathology (Vos et al., 2012). Overexpression of a yeast
complex I NADH dehydrogenase in pink1 mutant flies is also
able to rescue the mitochondrial pathology (Vilain et al.,
2012). Reversal of the bioenergetic deficit in both of these
models is sufficient to reverse the observed pathologies, sug-
gesting that impaired respiration and its consequences on
ATP production are fundamental to PINK1-associated PD
models, and may even precede aberrations observed in other
mitochondrial processes. Fibroblasts from patients with
PINK1 mutations also exhibit respiratory chain impairment
(Abramov et al., 2010; Rakovic et al., 2010). PINK1-deficient
human neuronal models display impaired respiration,
increased mitochondrial and cytosolic ROS production,
reduced ATP production and mitochondrial membrane
depolarization (Gandhi et al., 2009). Interestingly, the inhib-
ited respiration in PINK1-associated PD is secondary to the
reduced supply of respiratory chain substrates, and can be
reversed by improving the supply of complex I substrates,
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again supporting a central role for impaired bioenergetics
in PD.
PARKIN (PARK2) functions as an E3 ubiquitin protein
ligase that is mainly cytosolic but can translocate to damaged
mitochondria. parkin-deficient Drosophila models develop a
mitochondrial phenotype and neuronal degeneration that is
similar to pink1-deficient flies (Greene et al., 2003; Pesah
et al., 2004), and furthermore demonstrate a genetic interac-
tion between parkin and pink1 (Yang et al., 2006; Deng et al.,
2008). Additionally, parkin-deficient mitochondria have
decreased activity of complexes I and IV, increased ROS
species and increased sensitivity to complex I toxins
(Whitworth et al., 2005). Parkin-null mice display impaired
respiration in isolated striatal mitochondria and evidence of
oxidative damage to proteins and lipids (Palacino et al.,
2004), although in the absence of neurodegeneration (Itier
et al., 2003). Fibroblasts from PD patients with PARKIN muta-
tions show inhibited respiration and reduced ATP production
(Mortiboys et al., 2008).
DJ-1 is a small highly conserved protein that can be oxi-
dized at its cysteine residues during oxidative stress, and
therefore acts as an ROS scavenger (Taira et al., 2004). Oxida-
tive stress induces relocalization of DJ-1 from the cytosol to
the mitochondria (Canet-Aviles et al., 2004). Certain models
of DJ-1-deficient Drosophila demonstrate fragmented mito-
chondria, impaired bioenergetics, increased ROS production
and sensitivity to complex I toxins (Yang et al., 2005). DJ-1-
null mice do not develop overt neurodegeneration, although
they are more susceptible to MPTP-induced neurotoxicity
(Kim et al., 2005). Isolated mitochondria from DJ-1-null mice
also exhibit increased ROS levels (Andres-Mateos et al., 2007),
suggesting an antioxidant role for DJ-1. Several other roles
have also been proposed for DJ-1: DJ-1 binds RNA in an
oxidation- dependent manner, and its RNA targets include
mitochondrial genes and genes involved in glutathione
metabolism (van der Brug et al., 2008). DJ-1 stabilizes Nrf2,
which is a major regulator of the transcription of the antioxi-
dant response genes (Clements et al., 2006). DJ-1 acts as a
redox-sensitive molecular chaperone that can inhibit α-syn
aggregation (Shendelman et al., 2004). DJ-1 has also been
reported to act as a metal binding protein and, thus, protect
cells from copper and mercury-mediated cytotoxicity
(Bjorkblom et al., 2013).
α-syn is predominantly a presynaptic protein, but a sub-
population of α-syn localizes to mitochondrial membranes
under conditions of cellular stress or cytosolic acidification
(Cole et al., 2008), and it is also found in the mitochondria of
DA neurons in post-mortem human PD brains (Devi et al.,
2008). In cell models, overexpression of α-syn results in inhi-
bition of complex I and mitochondrial membrane depolari-
zation (Hsu et al., 2000). Transgenic mice overexpressing
A53T α-syn mutant under the mouse PrP promoter, show
neurodegeneration characterized by intraneuronal inclu-
sions, cell death and mitochondrial pathology, including
altered morphology, mitochondrial DNA damage and
oxidative-nitrative stress (Martin et al., 2006). α-syn trans-
genic mice also show defects in complex I activity in the SN
in the absence of neurodegeneration (Stichel et al., 2007).
Interestingly, α-syn knockout mice are resistant to the effects
of MPTP, suggesting that α-syn is required downstream of
complex I (Dauer et al., 2002). Importantly, the mitochon-
drial dysfunction and oxidative stress seen in PD promote
α-syn aggregation from its monomeric state to oligomers and
fibrils (Conway et al., 1998; Giasson et al., 2000). Hence, there
may be a bidirectional effect in which α-syn causes mito-
chondrial dysfunction, and this in turn exacerbates the
misfolding of α-syn. However, it is not clear whether mito-
chondrial respiratory chain impairment and oxidative stress
or α-syn aggregation is the initiating event in the pathogen-
esis of PD.
Mitochondrial calcium homeostasis and PD
Calcium homeostasis is critical to normal neuronal function.
Depolarization of the neuronal membrane induces opening
of voltage-gated calcium channels, resulting in an increase in
cytosolic calcium. The location, shape and amplitude of the
calcium signal are able to regulate diverse processes, such as
neurotransmitter release, vesicle recycling, axonal transport
and neuronal plasticity. It is therefore vital to be able to
modulate the peak and recovery of the calcium signal in
different ways at different cellular locations. This is achieved
in part by the ability of mitochondria to sequester and release
calcium ions (reviewed in Vos et al., 2010), thus maintaining
the large calcium gradient across the cell’s plasma membrane.
Mitochondrial calcium uptake is mediated by the negative
mitochondrial membrane potential and by a low-affinity
calcium uniporter. Once in the matrix, calcium is buffered by
forming reversible calcium phosphate complexes. Calcium
can then be extruded from mitochondria via the Na+/Ca2+
exchanger (reviewed in Rizzuto et al., 2012). The calcium-
buffering capacity of mitochondria is important in all
neurons, but it is particularly important in DA neurons; these
neurons utilize an autonomous pacemaker mechanism based
on L-type calcium channels, and are therefore exposed to
frequent influxes of calcium (Surmeier et al., 2011). This
places such neurons under increased demand for ATP to
maintain the cytosolic calcium concentration via ATP-
dependent pumps. Importantly, deregulated calcium uptake
or efflux leads to a state of mitochondrial calcium overload.
This results in opening of the mitochondrial permeability
transition pore, resulting in an influx of solutes into the
matrix, osmotic swelling and rupture of the outer mitochon-
drial membrane. Release of apoptotic mediators from the
intermembrane space into the cytosol is then able to trigger
cell death. Mitochondrial calcium overload is reported to
occur in rotenone models of PD, rendering rotenone-treated
cells vulnerable to glutamate excitotoxicity (Yadava and
Nicholls, 2007). Impaired mitochondrial efflux and mito-
chondrial calcium overload, with subsequent opening of the
permeability transition pore and apoptotic cell death, are also
reported in PINK1-deficient neurons (Gandhi et al., 2009;
Akundi et al., 2011). Mitochondria and the endoplasmic
reticulum (ER) are functionally and physically intercon-
nected at contact sites that enable high concentrations of
calcium to be generated (microdomains) and transferred to
mitochondria. This function is vital for calcium signalling.
There is evidence that α-syn, PARKIN and DJ-1 are necessary
for the ER-mitochondrial transfer of calcium, and that the
dysregulation of this process leads to abnormal mitochon-
drial calcium accumulation via an alteration in ER-
mitochondrial contact sites (Cali et al., 2012a; 2012b).
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Defective mitochondrial QC and PD
Mitochondrial QC mechanisms operate in a stepwise manner.
Firstly, molecular QC involves molecular chaperones and pro-
teases that assist the proper folding and assembly of mito-
chondrial proteins, and ensure the disposal of terminally
damaged proteins. Secondly, organellar QC ensures the
orderly disposal and recycling of terminally damaged mito-
chondria through mitophagy.
PINK1 and PARKIN are responsible for mitochondrial QC
maintenance. Loss-of-function mutations in these proteins
are associated with autosomal recessive parkinsonism
(Valente et al., 2004; Bonifati, 2007). Genetic studies in
Drosophila show that mitochondrial dysfunction due to
loss of function mutations in either pink1 or parkin, can
result in DA neuron degeneration (Whitworth et al.,
2005; Park et al., 2006). It has been shown that parkin
overexpression improves the mitochondrial phenotype in
pink1-deficient flies, supporting the concept that parkin
works genetically downstream of pink1. Accumulation of
dysfunctional mitochondria is found in the brains of PD
patients, highlighting the pivotal role of this pathway in PD
pathology.
The PINK1-PARKIN axis acts to guarantee mitochondrial
integrity at various levels. Upon mild mitochondrial dysfunc-
tion, PINK1 activates a molecular QC process, the mitochon-
drial unfolded-protein response (UPRmt). In the UPRmt,
molecular chaperones and proteases are modulated to
monitor the folding and assembly of mitochondrial proteins.
In this scenario, PINK1 induces activation of the serine pro-
tease high-temperature-regulated A2 (HtrA2) (Plun-Favreau
et al., 2007) and phosphorylation of mitochondrial chaper-
one receptor-associated protein 1 (TRAP1; Pridgeon et al.,
2007), to eliminate misfolded proteins and to restore
damaged mitochondria. It is reported that Htra2 knockout
mice show an accumulation of misfolded proteins in brain
mitochondria (Moisoi et al., 2009). In addition, the brains of
PD patients carrying mutations in PINK1 show a reduction in
HtrA2 phosphorylation (Plun-Favreau et al., 2007). Further-
more, loss of Trap1 in a Drosophila model causes a decline in
mitochondrial function, and restoration of its expression in
neurons rescues the phenotype of pink1 mutant flies (Costa
et al., 2013).
Valuable insights into the mechanisms regulating UPRmt
have been obtained from studies in Caenorhabditis elegans. In
this nematode, the mitochondrial matrix protease CLPP-1
acts as a stress sensor, and through its proteolytic activity,
transduces a signal to the cell nucleus that causes the tran-
scriptional activation of stress-related genes. This signalling
cascade involves the accumulation of the ubiquitin-like
protein UBL-5 (Benedetti et al., 2006) and the activation of
the transcription factor DVE-1 (Haynes et al., 2007). In addi-
tion, the transcription factor ATFS-1 is also capable of acti-
vating the UPRmt upon mitochondrial stress. Once in the
nucleus, ATFS-1 accumulates and activates the expression of
mitochondrial chaperones and other genes required to com-
pensate for metabolic stress (Nargund et al., 2012). The UPRmt
can also be activated by ‘mitonuclear imbalance’, an imbal-
ance between the expression of nuclear versus mitochondrial
encoded mitochondrial proteins (Houtkooper et al., 2013;
Mouchiroud et al., 2013). In this context, the central meta-
bolic intermediate, NAD+ positively regulates ageing by
enhancing the UPRmt. This occurs via NAD+-dependent sir-
tuins such as SIRT1 (Mouchiroud et al., 2013), which controls
mitochondrial biogenesis through the acetylation of targets
including the PPAR coactivator-1α (PGC-1α). It is therefore
attractive to consider whether targeting NAD+ metabolism is
a viable strategy to prevent age-associated neurodegenerative
diseases associated with mitochondrial dysfunction, such as
some forms of PD.
Mitophagy and PD
Once the molecular QC system is overwhelmed, organellar
QC processes form a second line of defence. Organellar QC
combines fusion, fission and mitophagy to promote the
sequestration, sorting and elimination of functionally
impaired mitochondria (Figure 1). PINK1 seems to have a
pivotal function in organellar QC; it recruits PARKIN to
impaired mitochondria, which targets them for mitophagy,
and thereby promotes the removal of defective mitochondria
(Figure 1B). The importance of the PINK1-PARKIN axis in
promoting organellar QC through mitophagy has been dem-
onstrated in vivo in Drosophila. Impairment of mitophagy in
pink1 and parkin mutant flies was shown to affect the turno-
ver of defective mitochondria, as well as the selective non-
mitophagic turnover of mitochondrial respiratory complexes
(Vincow et al., 2013), that accumulate in pink1 and parkin
mutant flies (de Castro et al., 2011). The PINK1-dependent-
recruitment of PARKIN to damaged mitochondria is also
reported to involve the F-box domain-containing protein
(Fbxo7; Burchell et al., 2013) and interestingly, mutations in
FBXO7 have been identified in families with autosomal reces-
sive early-onset PD, similar to that caused by mutations in
PINK1 or PARKIN (Shojaee et al., 2008; Di Fonzo et al., 2009;
Paisan-Ruiz et al., 2010). Additionally, PINK1 has been shown
to interact with components of the autophagy machinery
such as beclin1 (Michiorri et al., 2010) and LC3 (Kawajiri
et al., 2010).
If both molecular and organellar QC mechanisms fail to
rescue the damaged mitochondria, mitochondrial compo-
nents and pro-apoptotic proteins are released into the
cytosol, including cytochrome c (CytC); once released in
the cytosol, CytC activates the apoptotic pathway, causing
the irreversible demise of the cell (reviewed in Youle and
Strasser, 2008). In the light of these events, the importance of
the PINK1-PARKIN axis in maintaining both molecular and
organellar QC is clear. It is conceivable that mutations in
these genes in PD patients result in loss of function of these
proteins and thus failure of one of the QC systems. Failure of
one of these QC mechanisms ultimately results in loss of DA
neurons, and might have a causative role in PD.
Selective autophagy of mitochondria that are damaged
beyond the aid of molecular QC allows their basic macromol-
ecule components to be recycled. This selective mitochon-
drial autophagy (mitophagy) begins with the isolation of the
defective organelle in the autophagosome, which later fuses
with a lysosome to generate an autolysosome. Here, the
hydrolytic degradation of mitochondrial components takes
place. When failure of mitophagy occurs, damaged mito-
chondria may accumulate in the cell and may be detrimental
to cell function.
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Dysregulation of mitophagy is associated with neurode-
generative diseases such as PD (reviewed in Youle and
Narendra, 2011). The PD-related proteins PARKIN and PINK1
are potential regulators of mitophagy, ensuring the mainte-
nance of mitochondrial QC. Following mitochondrial
damage, PINK1 is required for the recruitment of PARKIN to
dysfunctional mitochondria to promote their degradation
(Matsuda et al., 2010; Narendra et al., 2010; Vives-Bauza et al.,
2010).
Furthermore, mitochondrial dynamics such as the fission
and fusion processes are important to maintain mitochon-
drial integrity. Fission is believed to be important for
mitophagy because this process is delayed by inhibition of
division. During PARKIN recruitment, mitochondrial dynam-
ics are shifted towards fission rather than fusion, partly due
to the degradation of mitofusins (MFNs; Gegg et al., 2010;
Tanaka et al., 2010; Ziviani et al., 2010) Moreover, many
mutations in mitochondrial fission/fusion genes, such as
MFN2, OPA1 and DRP1, are associated with neurodegenera-
tive diseases (Alexander et al., 2000; Zuchner et al., 2004).
Possible role of autophagy-inducing agents in
the modulation of mitophagy
A multitude of different agents can induce autophagy, but
their ability to induce mitophagy is debated. Rapamycin is a
metabolite isolated from the bacterial strain Streptomyces
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Figure 1
Modulation of mitochondrial dysfunction by the PINK1/PARKIN pathway. (A) Mitochondrial dynamics contribute to the maintenance of
mitochondrial integrity. Upon mitochondrial dysfunction, mtDNA mutations or misfolded proteins accumulate. The PINK1/PARKIN axis inhibits
the fusion process to avoid the spreading of damaged mitochondrial components. However, this axis also enhances the fission process to induce
the physical separation of damaged mitochondria. Healthy components are rescued and damaged ones are eliminated by mitophagy. (B)
Mitophagy is required to eliminate damaged mitochondria. When the organelle is deeply impaired, PINK1 recruits PARKIN for ubiquitination of
outer membrane proteins, which labels irreversibly damaged mitochondria for mitophagy. (C) Mitochondrial trafficking is arrested upon
mitochondrial dysfunction. PINK1 inhibits mitochondrial movement along microtubules, recruits PARKIN for ubiquitination and induces ubiquitin-
dependent degradation of Miro. The above information is summarized from references discussed in the text.
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hygroscopicus; the study of its action in yeast led to the dis-
covery of the protein target of rapamycin (TOR). The mam-
malian TOR (mTOR) is encoded by FRAP1 and acts as a sensor
of energy, nutrients, growth factors, redox and stress to
increase protein synthesis and inhibit autophagy.
Rapamycin is a well-known inducer of autophagy. Rapa-
mycin antagonizes mTOR, resulting in the activation of the
translation inhibitor 4E-BP. Moreover, it has been shown
that rapamycin treatment can improve mitochondrial
defects in cell lines generated from PD patients with PARKIN
mutations (Tain et al., 2009). Rapamycin-induced autophagy
was shown to suppress PD symptoms in a mouse model;
inhibition of mTOR by rapamycin also increased the lifes-
pan of mice by inducing a combination of increased
autophagy and decreased mRNA translation (Rieker et al.,
2011). Growing evidence indicates that autophagy can be
regulated by the UPR in response to ER stress (UPRER;
reviewed in Wouters and Koritzinsky, 2008). In this context,
salubrinal, a compound that protects cells from ER stress
by inhibiting the dephosphorylation of the eukaryotic
translation initiation factor 2 subunit α (Boyce et al., 2005),
was shown to enhance paraquat-induced autophagy (Niso-
Santano et al., 2011), as well as to mitigate DA neurodegen-
eration (Colla et al., 2012).
Metformin is a drug used for the treatment of type 2
diabetes; it reduces blood glucose, thus decreasing hepatic
gluconeogenesis and stimulating glucose uptake in muscle
(Stumvoll et al., 1995; Hundal et al., 2000). The mechanism of
action of metformin is based on the activation of AMP-
activated PK (AMPK), a protein that regulates energy metabo-
lism, and is activated by an imbalance in the AMP/ATP ratio.
A reduction in ATP levels promotes the phosphorylation of
multiple proteins by AMPK to activate ATP-generating path-
ways such as glycolysis. Therefore, AMPK can modulate a
variety of pathways, inhibiting the ones that are very energy
expensive. mRNA translation requires up to 45% of the total
cellular energy (Hardie, 2004); AMPK inhibits mRNA transla-
tion and promotes the activation of autophagy by inhibiting
mTOR. The ability of metformin to affect mitophagy has
been debated; the drug was found to affect erythrocyte
metabolism, a cell type that lacks mitochondria (Rapin et al.,
1991; Muller et al., 1997). In contrast, it has been recently
reported that metformin inhibits the mitochondrial respira-
tory chain complex I and prevents oxidative mitochondrial
phosphorylation, suggesting a role in the modulation of
mitochondrial metabolism (El-Mir et al., 2000). Furthermore,
it has been showed that metformin can reduce the risk of PD
in patients with type 2 diabetes (Wahlqvist et al., 2012). As
the modulation of autophagy is now possible using a variety
of therapeutic strategies (reviewed in Rubinsztein et al.,
2012), decreasing the activity of the mTOR pathway by
autophagy-inducing drugs could represent a promising target
for the treatment of neurodegenerative diseases.
Molecular scenario of mitochondrial
dynamics in the mitophagic pathway
Mitochondrial dynamics contribute to the maintenance of
mitochondrial integrity. Repetitive cycles of fusion and
fission occur to guarantee the presence of healthy mitochon-
dria in the cell and efficient distribution of their components
(mtDNA, proteins and respiratory chain components) during
mitochondrial turnover. These processes are regulated by
GTPases that operate on mitochondrial membranes. Mito-
chondrial fission ensures the separation of daughter mito-
chondria through GTPases acting on the outer membrane.
During fusion, different proteins act on the outer and inner
mitochondrial membranes.
Fission is mediated by dynamin-related protein 1 (DRP1)
through the formation of a multimeric complex; this
complex wraps around the outer mitochondrial membrane
(OMM), and causes physical scission of the membrane by
exerting a mechanical force. In contrast, fusion is mediated
by optic atrophy 1 (OPA1), MFN1 and MFN2 that act on
the inner and outer membranes. Depolarization of the mito-
chondrial membrane can influence the fusion process by
causing loss of OPA1 (Head et al., 2009) and the MFNs, result-
ing in mitochondrial fragmentation. Fragmented mitochon-
dria are often targeted for degradation through mitophagy
(Figure 1B).
Excessive fusion, due to overexpression of OPA1, prevents
mitophagy (Twig and Shirihai, 2011). Additionally, knock-
down of MFN2, precludes mitophagy by impairing the trans-
fer of lipids from mitochondria to autophagosomes (Hailey
et al., 2010). Conversely, fission is considered the prelude to
mitophagy. This notion is supported by genetic manipulation
in mammalian cells, where DRP1 silencing decreases
mitophagy (Twig et al., 2008).
Another important player in the machinery of mitochon-
drial dynamics is α-syn, a cytoplasmic protein discovered to
be the major component of intracellular aggregates (Lewy
bodies) that are common to most familial and sporadic PD
cases. α-syn can modulate the balance of mitochondrial
dynamics by inhibiting membrane fusion and causing
fragmentation through its interaction with the membrane
(Nakamura et al. 2011). α-syn down-regulation results in
elongated mitochondria in cell culture. In contrast, its over-
expression induces mitochondrial fragmentation, which is
rescued by co-expression of PINK1, PARKIN or DJ-1 (Kamp
et al., 2010). Overexpression of α-syn in neurons results in
fragmentation of mitochondria prior to cell death in a DRP1-
independent manner. In fact, the mitochondrial fragmenta-
tion is induced by a direct interaction of α-syn oligomers with
the mitochondrial membrane (Nakamura et al., 2011).
Ultimately, mitophagy requires proper functioning of
mitochondrial dynamics to avoid accumulation of damaged
mitochondria. An imbalance in the molecular machinery
towards fission, rather than fusion, promotes the clearance
of damaged mitochondria by mitophagy. In neurons, there
is an intimate link between mitochondrial dynamics and
mitophagy (reviewed in Van Laar and Berman, 2013). It was
reported that the Parkin-dependent mitophagy of depolar-
ized mitochondria in neurites required a block in mitochon-
drial transport, showing that these two processes are closely
linked (Cai et al., 2012). In support of this, it has been showed
that MFN2 is also involved in Parkin recruitment to damaged
mitochondria; moreover, PINK1 phosphorylates MFN2 and
promotes its degradation through PARKIN ubiquitination
(Chen and Dorn, 2013). Even though opposite effects on
mitochondrial dynamics have been proposed to be promoted
by the PINK1-PARKIN axis (reviewed in Van Laar and Berman,
2013), the observation that the fusion proteins MFN1 and
MFN2 are targets for PARKIN-dependent ubiquitination and
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degradation, supports a mechanism where the primary role of
the PINK1-PARKIN axis is to inhibit mitochondrial fusion.
Aberrant mitochondrial trafficking in PD
Mitochondrial trafficking is essential for all cells, but it is
particularly important for neurons due to their unique mor-
phology. Axons and dendrites extend for millimetres, even
up to centimetres in length. Synapses are often located at the
extremities of the cell, and require a considerable energy
supply; thus, the demand on mitochondrial ATP production
is very high. ATP cannot diffuse from the soma to distant
synapses; therefore, mitochondria are transported along
axons to provide ATP to meet local demands. The transport of
mitochondria in neurons from the cell soma along the axon
(anterograde axonal transport), occurs through the associa-
tion with the kinesin family motor proteins KIF1Bα and KIF5,
while the transport back to the cell soma (retrograde trans-
port), is mediated by cytosolic dynein (Hollenbeck and
Saxton, 2005; Hirokawa et al., 2010). The efficient transport
of mitochondria is vital in neurons as it is critical for synaptic
formation and function, via proper distribution of mitochon-
dria throughout neurites. In the soma, neurons have a highly
interconnected mitochondrial network together with well-
separated, individual mitochondria that travel up and down
an extensive network of axons and dendrites. In neurites
mitochondria provide energy in the form of ATP for synaptic
function, and act as a calcium-buffering system, ensuring
efficient synaptic transmission (Ly and Verstreken, 2006).
Consequently, the aberrant regulation of mitochondrial
transport, fission or fusion greatly alters synapse formation
and function (Li et al., 2004; 2008; Verstreken et al., 2005). As
a consequence of their highly specialized nature, the distri-
bution of mitochondria in neurons plays a key role in main-
taining neuronal energy reserves in multiple locations within
the same cell that, in turn, requires a delicate balance of
mitochondrial dynamics.
Recent studies have highlighted the presence of a motor/
adaptor complex on the mitochondrial surface that is respon-
sible for mitochondrial transport. This complex includes four
proteins: Miro (RhoT1/2), the heavy chain of kinesin-1,
Milton (TRAK1/2) and dynein. Milton mediates the binding
between kinesin-1 and Miro, and dynein interacts with
Milton and Miro (Stowers et al., 2002; Fransson et al., 2003;
2006; Guo et al., 2005; Glater et al., 2006).
Miro is a Rho GTPase protein that works as an anchor; it
is attached to the surface of the OMM, where it binds milton
(Glater et al., 2006). GTPase-defective mutants of Miro show
aggregation of mitochondria, suggesting that Miro has a role
in regulating mitochondrial trafficking, fusion and fission
(Fransson et al., 2006).
PINK1 and PARKIN are associated with the Miro/Milton
complex, suggesting the involvement of the PINK1/PARKIN
pathway in mitochondrial trafficking (Weihofen et al., 2009;
Wang et al., 2011). PINK1 phosphorylates Miro on several
sites, which induces ubiquitination by PARKIN and results in
proteasomal degradation of Miro. This results in the irrevers-
ible removal of the complex from the mitochondrial surface
and block of mitochondrial movement. pink1 knowdown in
Drosophila axons results in enhanced anterograde transport
(Liu et al., 2012), whereas overexpression of PINK1 or PARKIN
in both mammalian and Drosophila neurons results in inhi-
bition of mitochondrial trafficking (Figure 1C) (Chan et al.,
2011; Wang et al., 2011). In neurons, Parkin-dependent
mitophagy was reported to occur primarily in somatoden-
dritic compartments and not in axons (Cai et al., 2012).
During trafficking, mitochondria are more inclined to
fuse compared with when they are stationary (Liu and
Hajnoczky, 2009). The degradation of Miro by the PINK1/
PARKIN pathway is considered to be important to prevent
the fusion and the exchange of mitochondrial components
between damaged and healthy mitochondria. Indeed, mito-
chondrial transport defects caused by pink1 inactivation rep-
resent one of the key pathogenic events that contribute to PD
pathogenesis in the Drosophila model (Liu et al., 2012).
Because mutations in PINK1 and PARKIN are found in PD
patients, it is reasonable to propose that they can affect mito-
chondrial trafficking in PD patients.
Mitochondria, inflammation and PD
Failure of the organellar QC pathway, which ensures the
removal of damaged mitochondria through mitophagy, can
lead to the release of compartmentalized mitochondrial mol-
ecules. Once in the cytosol, some of these molecules, such as
CytC, Smac/DIABLO and HtrA2/OMI, are capable of activat-
ing apoptotic routines that lead to cell death. It is reported
that the failure of mitophagy results in the release of mtDNA
into the cell cytosol. In a manner similar to bacterial DNA,
mtDNA is capable of activating a Toll-like receptor (TLR)
9-mediated inflammatory response in cardiomyocytes, induc-
ing myocarditis and dilated cardiomyopathy (Oka et al.,
2012). Accordingly, defects in autophagy in LC3B knockout
mice result in the release of mtDNA into the cytosol, activa-
tion of caspase-1, and elevated levels of the pro-inflammatory
cytokine IL-β (Nakahira et al., 2011).
Data obtained from both post-mortem and in vivo studies
in PD patients suggest that neuroinflammatory mechanisms
could contribute to the non-cell autonomous death of dopa-
minergic neurons (Hirsch and Hunot, 2009). Accordingly, it is
conceivable that failure of mitochondrial clearance through
mitophagy in PD patients could be linked to inflammation by
promoting the activation of the TLR9 pathway. The TLR9-
mediated inflammatory response can increase the level of
pro-inflammatory cytokines, including IL-1β (Miura et al.,
2010). This cytokine plays a key role in the neuroinflamma-
tory processes in PD through at least two separate mecha-
nisms of neurotoxicity: direct binding to surface receptors on
dopaminergic neurons or activation of glial cells. Through
these mechanisms, IL-1β can activate cell death pathways
in dopaminergic neurons. Thus, the DNA released from
defective mitochondria that bypass mitophagy could be a
contributing factor in triggering the non-cell autonomous
dopaminergic cell death in PD.
Mitochondrial DNA deletions and misrepair
mechanisms in PD
Typically, human cells have between 50 and several hundred
mitochondria. Each mitochondrion has 5 to 10 copies of
mtDNA (Legros et al., 2004), contained in structures known
as nucleoids. As the mitochondrial genome is present in
multiple copies in each organelle, mutant mitochondrial
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genomes can coexist with normal genomes in a situation
known as heteroplasmy. This implies that once a critical
threshold of mutant DNA copies is reached, normal mito-
chondrial function may be altered. This may have important
consequences for cellular and organismal viability. The muta-
tion rate of mtDNA is known to be higher than nuclear DNA
(nDNA); in contrast to nDNA, mtDNA lacks protective
coating with histones. Furthermore, mtDNA is in close prox-
imity to the inner membrane, where DNA-damaging agents
such as ROS are continually produced. To counteract this
damage, mitochondria contain ROS-detoxifying enzymes
such as SOD2, and a group of repair enzymes that counteract
oxidative DNA damage. Among these, the orthologue of the
Escherichia coli MutT (MTH1) hydrolyses oxidized purine
nucleoside triphosphates, protecting mtDNA from the con-
sequences of mis-incorporation during replication or repair.
Increased levels of oxidized nucleosides are detected in
patients with neurological diseases such as PD (Nakabeppu,
2001). For example, increases in 8-oxoguanine, a purine
by-product of oxidative damage, can result in mismatched
pairing with adenine and cause G to T and A to C substitu-
tions in the genome. mtDNA mismatches can lead to mito-
chondrial impairment and cellular dysfunction, particularly
in post-mitotic cells with high energy demands such as skel-
etal muscle and neurons.
High levels of mtDNA deletions have been described in
the SN neurons in PD (Bender et al., 2006). One major
question is whether the accumulation of mtDNA mutations
contributes to PD pathogenesis by the gradual replacement
of wild-type DNA, failure to synthesize mitochondrial
proteins, causing respiratory chain deficiency, neuronal
dysfunction and ultimately, neuronal death. Post-mortem
studies of brains harbouring high levels of mtDNA deletions
(due to point mutations in the nuclear encoded mitochon-
drial DNA polymerase, POLG) demonstrate that such dele-
tions are indeed associated with complex I deficiency, but
that this is not necessarily correlated with parkinsonism
(Palin et al., 2013). mtDNA deletions and complex I defi-
ciency may occur with α-syn pathology but also exist
without any α-syn aggregation (Reeve et al., 2013), raising
the issue of whether a primary mitochondrial defect is
required for α-syn aggregation. Interestingly, transgenic
mice with a proofreading defective form of POLG (D257A)
show high levels of mtDNA deletions without significant
functional or morphological mitochondrial impairment,
and with no increased susceptibility to mitochondrial
toxins. Compensatory mechanisms, such as an increase in
mtDNA copy number and OPA1-related enhancement of
mitochondrial cristae, appeared to be responsible for pro-
tection of mitochondrial function and neuronal survival in
this study (Perier et al., 2013). Taken together, this work sug-
gests that primary mitochondrial defects cause an array of
phenotypes, some of which include PD-related neurodegen-
eration, although mitochondrial bioenergetic failure is
clearly possible in the absence of SN neuronal death,
protein aggregation and PD. However, it is possible that the
compensatory mechanisms for the initial defect may be
responsible for modulating which phenotype is seen, and
this highlights the importance of the balance between mito-
chondrial adaptation and QC mechanisms, and mitochon-
drial bioenergetic dysfunction.
Conclusions
The landscape of mitochondrial pathology in neurodegenera-
tion has radically transformed in the past 5 years. There is an
increasing body of evidence that mitochondrial pathology
has a primary role in the pathogenesis of certain genetic
forms of PD, although the evidence for its primary role over
other pathogenic processes in sporadic PD remains contro-
versial. Due to the inherent difficulty in identifying patho-
genesis in sporadic disease (that can only be currently studied
many years after the primary events have occurred), this
controversy is likely to remain for some time. There has been
a major shift in the view of mitochondria as ATP- and ROS-
producing organelles, to recognizing a much more diverse
role of mitochondria in trafficking, transport, QC and turno-
ver. For the past 20 years, the bioenergetic deficit has been the
most frequently recognized and well-characterized aspect of
mitochondrial pathology in most PD models. However, the
more recently discovered pathways may hold the key to
understanding how mitochondrial dysfunction leads to cell
death. The autosomal recessive models have uncovered the
importance of mitochondrial QC and transport for maintain-
ing neuronal function and integrity. The new key questions
are no longer simply whether a bioenergetic defect in
mitochondria is sufficient to cause PD, but whether a failure
in the mitochondrial compensatory mechanisms (transport,
dynamics and clearance) is sufficient, or necessary, to cause
PD. How a failure of mitochondrial transport and clearance
leads to gradual neuronal loss still remains to be explored, but
it is possible that it induces a modest but persistent disruption
to the cellular energy capacity, and this affects specific cellular
processes such as synaptic transmission and axonal transport
that would eventually lead to neuronal dysfunction and
death.
Mitochondrial QC pathways such as mitophagy can be
studied in isolation, for example, in cell cultures with differ-
ent mutations. However, it is clear that the in vivo models,
based on genetic forms of PD, show mitochondrial pathology
affecting several different pathways concomitantly: respira-
tory chain abnormalities, calcium dysregulation, mitochon-
drial morphology changes, altered dynamics and changes in
mitophagy. The processes responsible for counteracting mito-
chondrial dysfunction (Figure 2) are clearly interdependent
and interact with other mitochondrial processes in ways that
are not yet well understood. Unravelling the primary events
in mitochondrial dysfunction and the sequence of molecular
events that leads to cell death is a major challenge.
Future work should explore how these isolated processes
work in concert to result in neuronal death. There is some
evidence that the redox state and ROS levels of mitochondria
affect their dynamics. For example, inhibition of complexes I
and III can induce mitochondrial fission (Pletjushkina et al.,
2006). Conversely, mitochondrial fusion appears to enhance
ATP production (Mitra et al., 2009). In response to ROS pro-
duction, mitochondrial dynamics may be used to alter their
numbers or spatial distribution to sequester or limit local ROS
release. Mitophagy is now a well-characterized process that
occurs in response to damaged or depolarized mitochondria.
However, the upstream physiological processes that induce
such events in vivo are not well understood. The relationship
between mtDNA mutations, impaired energy production,
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excessive ROS production, fission–fusion processes and
mitophagy is unclear, but these processes are likely to be
interrelated. Elucidating the complexity of these interactions
will help to understand whether different PD proteins are
involved in distinct but overlapping functions within mito-
chondria, or whether they are all implicated in the same
pathway.
The relevance of such interactions is particularly impor-
tant when considering therapeutic options for PD. Based on
the hypothesis that respiratory chain impairment is sufficient
to induce neurodegeneration in PD models, there have been
extensive attempts to improve electron transport pharmaco-
logically using Co-enzyme Q10 (Co-Q10) and to scavenge
free radicals using vitamin E. Co-Q10 transfers electrons from
complexes I and II to complex III. In MPTP-treated mice and
primates, the administration of Co-Q10 exerts neuroprotec-
tive effects, reduces dopaminergic neuron death and attenu-
ates α-syn aggregation (Beal et al., 1998; Cleren et al., 2008).
Based on the recent reports in pink1-deficient flies, improving
respiratory chain function (using improved electron transfer)
should be sufficient to reverse mitochondrial deficits.
However, a large meta-analysis of vitamin E, Co-Q10 and
glutathione trials in PD patients, has not confirmed signifi-
cant benefits from any of these approaches (Weber and Ernst,
2006). The inability to translate the findings from the animal
models of PD to clinical benefit may be attributed to several
factors, such as the bioavailability of the reducing molecules
in the human brain and the effective targeting of mitochon-
dria. Finally, oxidative stress may need to be targeted in
the very early presymptomatic stages of the disease to be
effective.
The work highlighted in this review suggests further
reasons for the ineffectiveness of current antioxidant therapy
to date. Excessive ROS production may mediate toxicity by
affecting other processes, such as mitochondrial dynamics
and mitophagy, and these may not be effectively targeted by
current pharmacological methods. Up-regulation of 4E-BP by
the drug rapamycin activates autophagy and improves the
phenotype of pink1 and parkin mutant Drosophila (Tain et al.,
2009). This provides a rational basis for developing therapies
to target impaired mitophagy in PD. Therapeutic approaches
designed to enhance the activity of PINK1 have the potential
to suppress mitochondrial defects associated with PD-related
loss-of-function mutations in this gene. In this context, it was
demonstrated that the administration of the ATP analogue
kinetin triphosphate, a PINK1 neo-substrate, increases its
kinase activity and results in improved activation of the
PINK1-dependent mitochondrial QC (Hertz et al., 2013). This
indicates that employing pharmacological agents capable of
increasing PINK1 kinase function could be used for treating
diseases associated with defective mitochondrial QC such as
some forms of PD.
A final possibility remains that the mitochondrial dys-
function seen in PD is truly heterogeneous. There may be
multiple entry points in parallel processes that induce mito-
chondrial and neuronal dysfunction, and that ultimately
converge to induce cell death. In this scenario, it will be
necessary to design treatments that affect a range of targets
Healthy
mitochondria Mitophagy
Dysfuntional
mitochondria
(low)
Dysfuntional
mitochondria
(medium)
Dysfuntional
mitochondria
(high)
Activation of PINK1 pathway
TLR9, Caspase-1,
IL-1β
Inflammation
Release of
mitochondrial
DNA
TRAP1
Omi/HtrA2 
Parkin
dMfn2, VDAC1
Miro
Apoptosis
Release of
pro-apoptotic
proteins
CytC, Smac/
DIABLO,
Omi/HtrA2
Outcome
Molecular
effectors
Functional
status
Outcome
Mitochondrial damage
mtDNA mutations, impaired respiration,
reduced membrane potential, increased ROS
Figure 2
Cellular processes acting downstream of mitochondrial dysfunction. Increasing levels of mitochondrial damage lead to correspondingly higher
levels of mitochondrial dysfunction (here represented by the categorical classifiers ‘low’, ‘medium’ and ‘high’). Low levels of mitochondrial
dysfunction are counteracted at the molecular level by the PINK1 pathway. This acts on intra-organellar proteases and chaperones, such as
HtrA2/OMI and TRAP1, and suppresses the Miro-dependent transport of dysfunctional mitochondria. The combined output of these processes is
the restoration of mitochondrial health. Higher levels of mitochondrial dysfunction might overwhelm the molecular QC. In this case, PINK1
promotes the degradation of mitochondria with ‘medium’ levels of dysfunction through mitophagy. This is the organellar QC pathway. Finally,
if both molecular and organellar QC pathways downstream of PINK1 fail, the mitochondria will ultimately release pro-apoptotic proteins and
mtDNA, resulting in either apoptosis or inflammation. The above information is summarized from references discussed in the text.
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within the mitochondria to be effective. The complexity of
the mitochondrial pathology observed in neurodegenerative
diseases may thus require a complex therapeutic approach.
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